Jump Financial, LLC Xenon Pharmaceuticals Inc. Transaction History

Jump Financial, LLC

$4.56 Billion
Q3 2024

A detailed history of Jump Financial, LLC transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, Jump Financial, LLC holds 45,000 shares of XENE stock, worth $1.77 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

45,000

Previous 48,166 6.57%

Holding current value

$1.77 Million

Previous $1.88 Million 5.7%

% of portfolio

0.04%

Previous 0.04%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$36.12 - $43.96 $114,355 - $139,177	-3,166 Reduced 6.57%	45,000 $1.77 Million
Q2 2024 Aug 14, 2024	BUY	$36.25 - $43.75 $75,653 - $91,306	2,087 Added 4.53%	48,166 $1.88 Million
Q1 2024 May 13, 2024	BUY	$42.66 - $50.04 $941,890 - $1.1 Million	22,079 Added 92.0%	46,079 $1.98 Million
Q4 2023 Oct 21, 2024	SELL	$28.7 - $46.46 $693,564 - $1.12 Million	-24,166 Reduced 50.17%	24,000 $1.11 Million
Q4 2023 Feb 07, 2024	BUY	$28.7 - $46.46 $688,800 - $1.12 Million	24,000 New	24,000 $1.11 Million
Q4 2022 Feb 13, 2023	SELL	$33.06 - $39.43 $1.51 Million - $1.8 Million	-45,575 Reduced 85.51%	7,725 $304,000
Q3 2022 Nov 07, 2022	BUY	$30.79 - $39.82 $1.64 Million - $2.12 Million	53,300 New	53,300 $1.92 Million
Q2 2022 Aug 09, 2022	SELL	$25.44 - $35.16 $765,769 - $1.06 Million	-30,101 Closed	0 $0
Q1 2022 May 12, 2022	SELL	$25.09 - $33.13 $30,082 - $39,722	-1,199 Reduced 3.83%	30,101 $920,000
Q4 2021 Feb 10, 2022	BUY	$15.6 - $35.4 $488,280 - $1.11 Million	31,300 New	31,300 $978,000

Others Institutions Holding XENE

# of Institutions

212

Shares Held

70.2M

Call Options Held

88.3K

Put Options Held

28.8K

View Full List

About Xenon Pharmaceuticals Inc.

Ticker XENE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,263,500
Market Cap $2.45B
Description
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...

More about XENE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jump Financial, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jump Financial, LLC with notifications on news.

Account

Jump Financial, LLC Xenon Pharmaceuticals Inc. Transaction History